Jeffrey W. Albers - 27 May 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Director
Issuer ticker: SYRE
Reported as of: 27 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 17:56:32 UTC
Prior SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Jeffrey W. Albers filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 29 May 2026.

Key facts

This page summarizes Jeffrey W. Albers's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 May 2026, 17:56.

Change

Previous filing in this sequence was filed on 08 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001638474 Primary reporting owner

Albers Jeffrey W.

Relationship: Director
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Signature date: 29 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +8,026
Change %
Price: $0.000000^*
Shares after: 8,026
Date: 27 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,026
Exercise price: $72.51
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.